{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:43:54Z","timestamp":1793263434210,"version":"4.5.0"},"reference-count":219,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.semarthrit.2020.11.005","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T17:13:38Z","timestamp":1608225218000},"page":"219-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":277,"title":["C-reactive protein and implications in rheumatoid arthritis and associated comorbidities"],"prefix":"10.1016","volume":"51","author":[{"given":"Janet E.","family":"Pope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest H.","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.11.005_bib0001","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0002","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/annrheumdis-2011-200343","article-title":"The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review","volume":"71","author":"Bombardier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0003","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrrheum.2015.31","article-title":"Clocking in: chronobiology in rheumatoid arthritis","volume":"11","author":"Buttgereit","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0004","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semarthrit.2013.08.004","article-title":"Burden of disease in treated rheumatoid arthritis patients: going beyond the joint","volume":"43","author":"Cutolo","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","article-title":"Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity","volume":"70","author":"Strand","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0006","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0007","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrrheum.2013.212","article-title":"Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity","volume":"10","author":"Radner","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0008","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","article-title":"Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis","volume":"52","author":"Ranganath","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0009","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0010","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1136\/ard.2005.050377","article-title":"Patterns of cardiovascular risk in rheumatoid arthritis","volume":"65","author":"Solomon","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0011","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2011.75","article-title":"Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE","volume":"7","author":"Symmons","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0012","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0013","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/BOR.0000000000000470","article-title":"What are the dominant cytokines in early rheumatoid arthritis?","volume":"30","author":"Ridgley","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0014","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0014-5793(89)80476-4","article-title":"Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes","volume":"242","author":"Castell","year":"1989","journal-title":"FEBS Lett"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.5301\/jsrd.5000265","article-title":"Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis","volume":"2","author":"Choy","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0016","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/conmed-2018-000005","article-title":"Interleukin 6: the biology behind the therapy","volume":"2","author":"Jones","year":"2018","journal-title":"Consid Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0017","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12026-013-8384-0","article-title":"C-reactive protein and the biology of disease","volume":"56","author":"Ansar","year":"2013","journal-title":"Immunol Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0018","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","article-title":"Role of C-reactive protein at sites of inflammation and infection","volume":"9","author":"Sproston","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0019","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3349\/ymj.2011.52.1.113","article-title":"The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients","volume":"52","author":"Chung","year":"2011","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13075-015-0563-z","article-title":"Role of C-reactive protein in osteoclastogenesis in rheumatoid arthritis","volume":"17","author":"Kim","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/158514","article-title":"Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis","volume":"2010","author":"Meyer","year":"2010","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0022","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.clinbiochem.2010.07.012","article-title":"Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis","volume":"43","author":"Milman","year":"2010","journal-title":"Clin Biochem"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003199","article-title":"IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis","volume":"3","author":"Wang","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0024","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.4161\/cc.8.23.10068","article-title":"C-reactive protein: how conformational changes influence inflammatory properties","volume":"8","author":"Eisenhardt","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/372432","article-title":"Targeting C-reactive protein in inflammatory disease by preventing conformational changes","volume":"2015","author":"Thiele","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0026","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3389\/fimmu.2018.01351","article-title":"Dissociation of C-reactive protein localizes and amplifies inflammation: evidence for a direct biological role of c-reactive protein and its conformational changes","volume":"9","author":"McFadyen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0027","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4049\/jimmunol.1900172","article-title":"C-Reactive protein promotes inflammation through Fc\u03b3R-Induced glycolytic reprogramming of human macrophages","volume":"203","author":"Newling","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0028","article-title":"C-reactive protein: an in-depth look into structure, function, and regulation","volume":"2014","author":"Salazar","year":"2014","journal-title":"Int Sch Res Notices"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0029","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nature07468","article-title":"Structural recognition and functional activation of FcgammaR by innate pentraxins","volume":"456","author":"Lu","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0030","article-title":"Inflammation beyond the joints: rheumatoid arthritis and cardiovascular disease","volume":"2","author":"Urman","year":"2018","journal-title":"Scifed J Cardiol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0031","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2005.03.031","article-title":"Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein","volume":"184","author":"Devaraj","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0032","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0033","unstructured":"FDA. Review Criteria for Assessment of C Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Protein (cCRP) Assays - Guidance for Industry and FDA Staff, <https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/review-criteria-assessment-c-reactive-protein-crp-high-sensitivity-c-reactive-protein-hscrp-and>(2005)."},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0034","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/obr.12003","article-title":"Obesity and C-reactive protein in various populations: a systematic review and meta-analysis","volume":"14","author":"Choi","year":"2013","journal-title":"Obes Rev"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","article-title":"Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries","volume":"57","author":"Kilcher","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0036","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/ar4469","article-title":"Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year","volume":"16","author":"Kay","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0037","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3899\/jrheum.080770","article-title":"Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%--45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States","volume":"36","author":"Sokka","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0038","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s13075-014-0475-3","article-title":"CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients","volume":"16","author":"Ammitzb\u00f8ll","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0039","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/gene.2015.24","article-title":"The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis","volume":"16","author":"Danila","year":"2015","journal-title":"Genes Immun"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000341","article-title":"A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation","volume":"7","author":"Rhodes","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0041","doi-asserted-by":"crossref","first-page":"R214","DOI":"10.1186\/ar4052","volume":"14","author":"Plant","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0042","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3390\/nu10101535","article-title":"Poor dietary quality is associated with increased inflammation in swedish patients with rheumatoid arthritis","volume":"10","author":"B\u00e4rebring","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0043","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/art.23766","article-title":"Association of body fat with C-reactive protein in rheumatoid arthritis","volume":"58","author":"Giles","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0044","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/03009740903270607","article-title":"The association of luteinizing hormone and follicle-stimulating hormone with cytokines and markers of disease activity in rheumatoid arthritis: a case-control study","volume":"39","author":"K\u00e5ss","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0045","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1136\/ard.2004.032151","article-title":"Increased C reactive protein in response to acute stress in patients with rheumatoid arthritis","volume":"64","author":"Veldhuijzen van Zanten","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0046","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fmed.2018.00185","article-title":"The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis","volume":"5","author":"Orr","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2015.12.021","article-title":"Effects of C-reactive protein on bone cells","volume":"145","author":"Cho","year":"2016","journal-title":"Life Sci"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0048","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fimmu.2018.00234","article-title":"Monomeric C-reactive protein binds and neutralizes receptor activator of NF-\u03baB ligand-induced osteoclast differentiation","volume":"9","author":"Jia","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0049","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3389\/fimmu.2017.01958","article-title":"M1 and M2 monocytes in rheumatoid arthritis: a contribution of imbalance of M1\/M2 monocytes to osteoclastogenesis","volume":"8","author":"Fukui","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2478\/v10039-010-0006-7","article-title":"Relationship between serum acute-phase proteins and high disease activity in patients with rheumatoid arthritis","volume":"55","author":"Cylwik","year":"2010","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0051","first-page":"423","article-title":"Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis","volume":"34","author":"Yildirim","year":"2004","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0052","first-page":"1095","article-title":"High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis","volume":"31","author":"Dessein","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0053","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/ard.59.3.223","article-title":"Predictors of functional status in patients with early rheumatoid arthritis","volume":"59","author":"Jansen","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0054","first-page":"814","article-title":"Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients","volume":"26","author":"Keenan","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/03009742.2015.1095943","article-title":"Correlations between fatigue and disease duration, disease activity, and pain in patients with rheumatoid arthritis: a systematic review","volume":"45","author":"Madsen","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0056","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2474-3-18","article-title":"Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis","volume":"3","author":"Sarzi-Puttini","year":"2002","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0057","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0058","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0059","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0060","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0061","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/183653","article-title":"Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis","volume":"2013","author":"Ally","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0062","first-page":"1","article-title":"Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies","author":"Curtis","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0063","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00296-007-0357-y","article-title":"Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis","volume":"27","author":"Emery","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0064","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/ard.60.10.924","article-title":"Predictors of radiographic joint damage in patients with early rheumatoid arthritis","volume":"60","author":"Jansen","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0065","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/rheumatology\/keu413","article-title":"Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review","volume":"54","author":"Navarro-Comp\u00e1n","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0066","first-page":"kez542","article-title":"An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases","author":"Vanier","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0067","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41927-019-0052-0","article-title":"Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis","volume":"3","author":"Bay-Jensen","year":"2019","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0068","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3390\/jcm7110439","article-title":"Non-hepatic alkaline phosphatase, hs-CRP and progression of vertebral fracture in patients with rheumatoid arthritis: a population-based longitudinal study","volume":"7","author":"Yeh","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0069","article-title":"Cardiovascular event risk in rheumatoid arthritis compared with type 2 Diabetes: a 15-year longitudinal study","author":"Agca","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0070","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0071","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0072","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151245","article-title":"Rheumatoid arthritis and incidence of twelve initial presentations of cardiovascular disease: a population record-linkage cohort study in England","volume":"11","author":"Pujades-Rodriguez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0073","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.semarthrit.2018.03.005","article-title":"Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis","volume":"48","author":"Cooksey","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0074","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157360","article-title":"Rheumatoid Arthritis disadvantages younger patients for cardiovascular diseases: a meta-analysis","volume":"11","author":"Fransen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0076","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0077","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","article-title":"Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment","volume":"53","author":"Choy","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0078","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0079","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0080","doi-asserted-by":"crossref","first-page":"483","DOI":"10.7326\/0003-4819-151-7-200910060-00009","article-title":"C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force","volume":"151","author":"Buckley","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0081","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0082","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fimmu.2018.00430","article-title":"C-reactive protein in atherothrombosis and angiogenesis","volume":"9","author":"Badimon","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0083","doi-asserted-by":"crossref","first-page":"685","DOI":"10.15537\/smj.2015.6.10557","article-title":"Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity","volume":"36","author":"Attar","year":"2015","journal-title":"Saudi Med J"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0084","doi-asserted-by":"crossref","first-page":"e68975","DOI":"10.1371\/journal.pone.0068975","article-title":"LDL cholesterolemia as a novel risk factor for radiographic progression of rheumatoid arthritis: a single-center prospective study","volume":"8","author":"Park","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0085","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/annrheumdis-2013-204715","article-title":"The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0086","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0087","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/annrheumdis-2013-204987","article-title":"Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration","volume":"75","author":"Navarro-Mill\u00e1n","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0088","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.22482","article-title":"HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis","volume":"57","author":"Gonzalez-Gay","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0089","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/art.21204","article-title":"Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort","volume":"52","author":"Goodson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0090","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1160\/TH14-11-0921","article-title":"Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies","volume":"113","author":"Ambrosino","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0091","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/art.30542","article-title":"Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis","volume":"63","author":"Giles","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0092","first-page":"1219","article-title":"High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis","volume":"32","author":"Gonzalez-Gay","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0093","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-019-1975-y","article-title":"Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study","volume":"21","author":"Ruscitti","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0094","volume":"2015","author":"V\u00e1zquez-Del Mercado","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0095","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0096","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0097","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007393","article-title":"Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study","volume":"7","author":"Kang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0098","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0099","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0100","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","article-title":"Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up","volume":"59","author":"Fleischmann","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0101","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0102","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3899\/jrheum.100346","article-title":"Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease","volume":"38","author":"Crowson","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0104","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/03009742.2011.626443","article-title":"Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity","volume":"41","author":"da Cunha","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170361","article-title":"Metabolic syndrome and its components among rheumatoid arthritis patients: a comprehensive updated systematic review and meta-analysis","volume":"12","author":"Hallajzadeh","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0106","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/acr2.11075","article-title":"Prevalence and characteristics of metabolic syndrome differ in men and women with early rheumatoid arthritis","volume":"1","author":"Kuriya","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0107","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5606\/ArchRheumatol.2017.5949","article-title":"Prevalence of metabolic syndrome in treatment na\u00efve rheumatoid arthritis and correlation with disease parameters","volume":"32","author":"Pandey","year":"2016","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0108","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00296-015-3307-0","article-title":"Differences in the prevalence and characteristics of metabolic syndrome in rheumatoid arthritis and osteoarthritis: a multicentric study","volume":"35","author":"\u0160alamon","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0109","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1002\/art.27629","article-title":"Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics","volume":"62","author":"Giles","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0110","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4081\/reumatismo.2018.1061","article-title":"Inflammatory markers predict insulin sensitivity in active rheumatoid arthritis but not in psoriatic arthritis","volume":"70","author":"Bellan","year":"2018","journal-title":"Reumatismo"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0111","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/art.23600","article-title":"Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms","volume":"58","author":"Chung","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0112","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar428","article-title":"Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis","volume":"4","author":"Dessein","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0113","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/art.22053","article-title":"Insulin resistance and impaired beta cell function in rheumatoid arthritis","volume":"54","author":"Dessein","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0114","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/art.38986","article-title":"Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis","volume":"67","author":"Giles","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001588","article-title":"The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis","volume":"4","author":"Liao","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0116","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cca.2018.08.028","article-title":"Association of serum lipids with autoantibodies and inflammatory markers in rheumatoid arthritis patients","volume":"486","author":"Gan","year":"2018","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0117","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0118","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.3390\/ijms20184633","article-title":"Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis","volume":"20","author":"Hoffman","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0119","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12944-019-0994-7","article-title":"Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"18","author":"Qiu","year":"2019","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0121","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","article-title":"Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies","volume":"77","author":"Taylor","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0122","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1574887113666180314100340","article-title":"Insulin-sensiting effects of tumor necrosis factor alpha inhibitors in rheumatoid arthritis: a systematic review and meta-analysis","volume":"13","author":"Leporini","year":"2018","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0123","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3874","article-title":"Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance","volume":"14","author":"Stagakis","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0124","doi-asserted-by":"crossref","first-page":"R160","DOI":"10.1186\/ar3900","article-title":"Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis","volume":"14","author":"Stavropoulos-Kalinoglou","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0125","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jcsm.12189","article-title":"Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis","volume":"8","author":"Tournadre","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0126","first-page":"310","article-title":"Patients with newly diagnosed rheumatoid arthritis are at increased risk of diabetes mellitus: an observational cohort study","volume":"42","author":"Emamifar","year":"2017","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0127","first-page":"115","article-title":"Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis","volume":"33","author":"Jiang","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0128","doi-asserted-by":"crossref","first-page":"e7896","DOI":"10.1097\/MD.0000000000007896","article-title":"Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: results from a cross-sectional study","volume":"96","author":"Ruscitti","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/rheumatology\/kex414","article-title":"High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data","volume":"57","author":"Albrecht","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0130","doi-asserted-by":"crossref","first-page":"e2552","DOI":"10.1097\/MD.0000000000002552","article-title":"Prevalence of undiagnosed diabetes in rheumatoid arthritis: an OGTT study","volume":"95","author":"Ursini","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0131","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2016-209954","article-title":"Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis","volume":"76","author":"Ozen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0132","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.2011.878","article-title":"Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis","volume":"305","author":"Solomon","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210459","article-title":"Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis","volume":"14","author":"Lillegraven","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0134","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196368","article-title":"Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study","volume":"13","author":"Otsuka","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0135","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez106.053","article-title":"Effect of sarilumab on glycosylated hemoglobin in patients with rheumatoid arthritis and diabetes","volume":"58","author":"Burmester","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0136","doi-asserted-by":"crossref","DOI":"10.1177\/2235042X18820209","article-title":"Chronic obstructive pulmonary disease and rheumatic diseases: a systematic review on a neglected comorbidity","volume":"9","author":"Gergianaki","year":"2019","journal-title":"J Comorb"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0137","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12931-019-1123-x","article-title":"Chronic obstructive pulmonary disease in rheumatoid arthritis: a systematic review and meta-analysis","volume":"20","author":"Ma","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0138","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.semarthrit.2017.09.005","article-title":"Rheumatoid arthritis and risk of chronic obstructive pulmonary disease or asthma among women: a marginal structural model analysis in the Nurses' Health Study","volume":"47","author":"Sparks","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0139","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jbspin.2015.05.016","article-title":"Risk of incident chronic obstructive pulmonary disease in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"83","author":"Ungprasert","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rmed.2018.06.010","article-title":"Increased mortality among patients with rheumatoid arthritis and COPD: a population-based study","volume":"140","author":"Hyldgaard","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0141","first-page":"kez409","article-title":"Prognostic value of comorbidity indices and lung diseases in early rheumatoid arthritis: a UK population-based study","author":"Nikiphorou","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0142","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5588\/ijtld.18.0228","article-title":"Elucidating the risk factors for chronic obstructive pulmonary disease: an umbrella review of meta-analyses","volume":"23","author":"Bellou","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0143","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejim.2007.04.026","article-title":"The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease","volume":"19","author":"Karadag","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0144","doi-asserted-by":"crossref","first-page":"e22831","DOI":"10.1002\/jcla.22831","article-title":"Correlations between serum amyloid A, C-reactive protein and clinical indices of patients with acutely exacerbated chronic obstructive pulmonary disease","volume":"33","author":"Lin","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0145","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/crj.12752","article-title":"Blood biomarkers as predictors of long-term mortality in COPD","volume":"12","author":"Mendy","year":"2018","journal-title":"Clin Respir J"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0146","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0070-2016","article-title":"C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis","volume":"26","author":"Leuzzi","year":"2017","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0147","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/COPD.S118153","article-title":"COPD assessment test score and serum C-reactive protein levels in stable COPD patients","volume":"11","author":"Kang","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0148","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/COPD.S87015","article-title":"C-reactive protein levels in stable COPD patients: a case-control study","volume":"10","author":"Silva","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0149","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0150","first-page":"kez359","article-title":"Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study","author":"Hudson","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0151","doi-asserted-by":"crossref","unstructured":"Kang, E.H. et\u00a0al. Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study. Semin Arthritis Rheu, 2020;50:401--8. doi:10.1016\/j.semarthrit.2019.11.010.","DOI":"10.1016\/j.semarthrit.2019.11.010"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0152","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3390\/jcm8122038","article-title":"Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians","volume":"8","author":"Bendstrup","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0153","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0154","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/rccm.201411-1950OC","article-title":"Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers","volume":"191","author":"Doyle","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0155","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","article-title":"A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality","volume":"76","author":"Hyldgaard","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0156","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/ajrccm.156.2.9609016","article-title":"Interstitial lung disease in recent onset rheumatoid arthritis","volume":"156","author":"Gabbay","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0157","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics - a large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0158","first-page":"344","article-title":"Patterns of interstitial lung disease and mortality in rheumatoid arthritis","volume":"56","author":"Zamora-Legoff","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0159","first-page":"21","article-title":"Rheumatoid arthritis-associated interstitial lung disease","volume":"4","author":"Solomon","year":"2012","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0160","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0161","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.rmed.2013.05.002","article-title":"Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD)","volume":"107","author":"Solomon","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0162","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.rmed.2017.03.027","article-title":"High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: relationship to survival","volume":"126","author":"Yunt","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0163","doi-asserted-by":"crossref","first-page":"708","DOI":"10.12659\/MSM.890880","article-title":"A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients","volume":"21","author":"Wang","year":"2015","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0164","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3904\/kjim.2016.349","article-title":"Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis","volume":"34","author":"Yang","year":"2019","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0165","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10067-017-3561-5","article-title":"Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease","volume":"36","author":"Zhang","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0166","doi-asserted-by":"crossref","first-page":"e17088","DOI":"10.1097\/MD.0000000000017088","article-title":"High-resolution computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities","volume":"98","author":"Salaffi","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0167","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/rheumatology\/ket169","article-title":"The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis","volume":"52","author":"Matcham","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0168","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbi.2015.06.001","article-title":"Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder","volume":"49","author":"Haapakoski","year":"2015","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0169","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/1756-185X.13529","article-title":"Interleukin-6 and interleukin-17 are related to depression in patients with rheumatoid arthritis","volume":"22","author":"Li","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biopsycho.2009.02.003","article-title":"Association between C-reactive protein and depressive symptoms in women with rheumatoid arthritis","volume":"81","author":"Low","year":"2009","journal-title":"Biol Psychol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0171","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/art.24647","article-title":"Depression, inflammation, and pain in patients with rheumatoid arthritis","volume":"61","author":"Kojima","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0172","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5954897","article-title":"Influence of biological therapeutics, cytokines, and disease activity on depression in rheumatoid arthritis","volume":"2018","author":"Figueiredo-Braga","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0173","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/rheumatology\/kev306","article-title":"Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial","volume":"55","author":"Matcham","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0174","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13075-018-1645-5","article-title":"Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)","volume":"20","author":"Sergeant","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0175","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/rheumatology\/kex528","article-title":"The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology Biologics Register","volume":"57","author":"Matcham","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0176","first-page":"30","article-title":"Tumor necrosis factor inhibitor therapy and the risk for depression among working-age adults with rheumatoid arthritis","volume":"12","author":"Deb","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0177","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychores.2015.04.008","article-title":"Tumour necrosis factor-alpha inhibitor therapy in chronic physical illness: a systematic review and meta-analysis of the effect on depression and anxiety","volume":"79","author":"Abbott","year":"2015","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0178","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/rheumatology\/kev442","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis","volume":"55","author":"Strand","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0179","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13075-016-1096-9","article-title":"Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial","volume":"18","author":"Strand","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0180","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000496","article-title":"Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials","volume":"3","author":"Strand","year":"2017","journal-title":"RMD Open"},{"issue":"SAT0182","key":"10.1016\/j.semarthrit.2020.11.005_bib0181","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2018-eular.2176","article-title":"Tocilizumab s.c. \u2013 improvement of the depressiveness, fatigue and pain in RA therapy","volume":"77","author":"Behrens","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0182","doi-asserted-by":"crossref","first-page":"e15947","DOI":"10.1097\/MD.0000000000015947","article-title":"Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study","volume":"98","author":"Corominas","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0183","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.clinthera.2016.06.007","article-title":"A prospective evaluation of the effects of prevalent depressive symptoms on disease activity in rheumatoid arthritis patients treated with biologic response modifiers","volume":"38","author":"Rathbun","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0184","doi-asserted-by":"crossref","first-page":"e5781","DOI":"10.1097\/MD.0000000000005781","article-title":"No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: a cross-sectional study and theoretical consideration","volume":"96","author":"Hansen","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0185","first-page":"2359","article-title":"Do elevated levels of serum C-reactive protein predict rheumatoid arthritis in men: correlations with pre-RA status and baseline positive rheumatoid factors","volume":"28","author":"Masi","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0186","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/archinte.166.22.2490","article-title":"C-reactive protein in the prediction of rheumatoid arthritis in women","volume":"166","author":"Shadick","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0187","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000382","article-title":"DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0188","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/rheumatology\/key374","article-title":"Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis","volume":"58","author":"Hamann","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0189","first-page":"799","article-title":"Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis","volume":"35","author":"Kuriya","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-017-1346-5","article-title":"Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition","volume":"19","author":"Schoels","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0191","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3899\/jrheum.140717","article-title":"Arthritis clinical trials at a crossroad","volume":"42","author":"Pope","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0192","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0193","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/kex038","article-title":"Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries","volume":"56","author":"Crowson","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0194","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41927-018-0014-y","article-title":"Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment","volume":"2","author":"Jagpal","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0195","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/art.40532","article-title":"Impact of changes in inflammation on estimated ten-year cardiovascular risk in rheumatoid arthritis","volume":"70","author":"Yu","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0196","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/rheumatology\/kew440","article-title":"Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis","volume":"56","author":"Alemao","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0197","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/acr.22553","article-title":"Trends in excess mortality among patients with rheumatoid arthritis in Ontario, Canada","volume":"67","author":"Widdifield","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0198","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/ar2669","article-title":"Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases","volume":"11","author":"Gabriel","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0199","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/ard.56.1.27","article-title":"The timing of glucocorticoid administration in rheumatoid arthritis","volume":"56","author":"Arvidson","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0201","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000607","article-title":"Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study","volume":"4","author":"Gabay","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0202","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","article-title":"Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial","volume":"73","author":"Huizinga","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0203","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3889\/oamjms.2019.278","article-title":"Values and correlations between C-reactive protein and apolipoprotein B after treatment with methotrexate at patients with rheumatoid arthritis","volume":"7","author":"Ismaili","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0204","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/acr.22384","article-title":"Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"66","author":"Kivitz","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0205","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0206","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0207","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/acr.23303","article-title":"Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic agent in a global comparative observational study","volume":"69","author":"Choy","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0208","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0209","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0210","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0211","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0212","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcph.826","article-title":"Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA","volume":"57","author":"Abdallah","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0213","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/acr.22765","article-title":"Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis","volume":"68","author":"Wang","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0214","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0215","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0216","doi-asserted-by":"crossref","unstructured":"van der Heijde, D. et\u00a0al. SAT0058\u2005consistency of radiographic responses with Sarilumab plus methotrexate across subpopulations of patients with rheumatoid arthritis in a phase 3 study. Ann Rheum Dis 2016;75:685. (SAT0058), doi: 10.1136\/annrheumdis-2016-eular.","DOI":"10.1136\/annrheumdis-2016-eular.4363"},{"issue":"SAT0202","key":"10.1016\/j.semarthrit.2020.11.005_bib0217","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/annrheumdis-2017-eular.4540","article-title":"SAT0202\u2005Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with active rheumatoid arthritis in the phase 3 monarch study, including subpopulations","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0218","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1132-9","article-title":"Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY","volume":"18","author":"Boyapati","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.11.005_bib0219","first-page":"568","volume":"36","author":"Juhl","year":"2018","journal-title":"Clin Exp Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:06:23Z","timestamp":1758733583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220302900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":219,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0049017220302900"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.11.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C-reactive protein and implications in rheumatoid arthritis and associated comorbidities","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}